August 11, 2016 / 11:47 AM / a year ago

BRIEF-Resverlogix announces positive recommendation from data safety monitoring board for Apabetalone phase 3 study

Aug 11 (Reuters) - Resverlogix Corp

* Resverlogix announces positive recommendation from data safety monitoring board for phase 3 study of Apabetalone (rvx-208)

* Data review by independent data safety monitoring board resulted in verbal recommendation for Betonmace trial to continue as planned

* Dsmb reviewed available study data and noted that no safety or efficacy concerns were identified Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below